ArticleHealth science reports2023
Economic burden of type 2 diabetes in Iran: A cost-of-illness study.
Article in Health science reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Health economic evaluation of structured education programs for patients with diabetes: a systematic review.Frontiers in public health · 2024Pooled it
- Trial
- Effect of health literacy-based teach-back training on quality of life and treatment adherence in type 2 diabetes: an experimental study.Scientific reports · 2025Trial
- Risk assessment for type 2 diabetes mellitus and its association with knowledge and health beliefs among university students in three Arab countries.Scientific reports · 2026Article
- The effectiveness of educational intervention based on the theory of planned behavior on nutritional behaviors of type 2 diabetic patients in Northeastern Iran.Journal of education and health promotion · 2026Article
- Antibiotic consumption and medication cost in diabetic patients: Insights from Iran health insurance organization (IHIO) claims data.PloS one · 2026Article
- Cost-effectiveness analysis of a community pharmacist-based intervention to prevent cardiovascular complications in patients with type 2 diabetes in Iran.Cost effectiveness and resource allocation : C/E · 2025Article
- Economic Burden of Obesity in Iran University of Medical Sciences: A Cost Analysis Using the Cost of Illness Framework.Health science reports · 2025Article
- Financial and Treatment Compliance Challenges Among Diabetic Patients: A Cross-Sectional Study From Pakistan.Cureus · 2025Article
- Economic burden of Type 2 diabetes in Iran in 2022.BMC public health · 2025Article
- Article
- Impact of vitamin D on glycemic control and microvascular complications in type 2 diabetes: A cross-sectional study.PloS one · 2025Article
- A Consensus Report on Management of Type 2 Diabetes Mellitus in Iran.Medical journal of the Islamic Republic of Iran · 2025Article
- Naringin Prevents Diabetic-Induced Dysmetabolism in Male Wistar Rats by Modulating GSK-3 Activities and Oxidative Stress-Dependent Pathways.Cell biochemistry and biophysics · 2024Article
- Sleep quality and glycemic control in adults with type 2 diabetes mellitus.Journal of family medicine and primary care · 2024Article
- Economic burden of diabetic foot ulcer: a case of Iran.BMC health services research · 2024Article
- Association of educational attainment with hypertension and type-2 diabetes: A Mendelian randomization study.SSM - population health · 2024Article
- Appraisal the structure of diabetes self-management education and support in diabetes education units of Isfahan, Iran.Journal of education and health promotion · 2024Article
- The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial.Health promotion perspectives · 2024Article
- Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Type 2 diabetes mellitus (T2DM) is a prevalent public health problem worldwide, and the economic burden of the disease poses one of the main challenges for health systems in low- and middle-income countries. This study aimed to estimate the economic burden of T2DM in Iran, in 2018. Methods: This was a cost-of-illness study. Three hundred and seventy-five patients with T2DM who were referred to Imam Reza and Sina's educational and therapeutic centers and Asad Abadi clinic in Tabriz, Iran, in 2018 were included. A researcher-constructed checklist was used for data collection. Data were analyzed using EXCEL and SPSS software version 22. Results: Total economic burden of diabetes was estimated at 152,443,862,480.3 (purchasing power parity [PPP], Current International $) (approximately 7.69% of GDP, PPP, Current International $). The mean total direct and indirect costs were 11,278.68 (PPP) (62.35% of mean total cost) and 6808.88 (PPP, Current International $) (37.64% of the total cost), respectively. The mean total direct medical cost and the direct nonmedical cost were 10,819.43 (PPP, Current International $) (59.81% of mean total cost) and 459.24 (PPP, Current International $) (2.53% of mean total cost) per patient, respectively. Besides, the mean direct medical cost was 6.18 times the total per capita expenditure on health, and the total direct medical cost was 8.9% times the total expenditure on health. Conclusion: Diabetes imposes a substantial economic burden on patients, health systems, and the whole economy. Besides, since the cost of the disease in patients treated with insulin and those with diabetes complications is significantly higher, the reinforcement of self-care measures and focusing on modifying lifestyle (dietary modification and physical activity) in patients with T2DM can significantly reduce the costs of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.